Pharmala Biotech Holdings Inc. (MDMA.CN)
Pharmala Biotech Holdings Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $0.17, up 3.03% on the session, giving a market capitalisation of $18.6M. Its beta of 0.75 implies it has historically moved less than the broad market.
Pharmala Biotech Holdings Inc., operating as PharmAla, concentrates its efforts on the research, manufacturing, and bringing to market of active pharmaceutical ingredients (APIs) within the substituted methylenedioxy-phenethylamine (MDXX) class. The company's offerings further extend to various MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB) and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), in addition to prepared formulations of these MDXX substances. The enterprise maintains its primary corporate offices in Vancouver, Canada.
Pharmala Biotech Holdings Inc. is most often compared with the following Healthcare names: